SciSparc (SPRC) Liabilities and Shareholders Equity (2016 - 2025)
SciSparc (SPRC) posted Liabilities and Shareholders Equity of $7.6 million for Q4 2025, up 48.32% sequentially from $5.1 million in Q2 2025, and down 26.34% YoY from $10.3 million in Q4 2024.
SciSparc (SPRC) Liabilities and Shareholders Equity (2016 - 2025) Analysis & Trends
SciSparc has reported Liabilities and Shareholders Equity for 10 years, with the latest figure at $7.6 million in Q4 2025.
- Quarterly Liabilities and Shareholders Equity fell 26.34% year-over-year to $7.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $33.6 million (down 19.84% YoY) and the FY2025 annual result came in at $7.6 million, down 26.34% from the prior year.
- Liabilities and Shareholders Equity rose to $7.6 million in Q4 2025 per SPRC's latest filing, from $5.1 million in the prior quarter.
- Over five years, Liabilities and Shareholders Equity peaked at $14.4 million in Q2 2022 and troughed at $5.1 million in Q2 2025.
- A 5-year average of $10.2 million and a median of $10.3 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
- The sharpest annual moves came in 2021 and 2025: Liabilities and Shareholders Equity surged 423.67% in 2021, then sank 50.97% in 2025.
- Over 5 years, Liabilities and Shareholders Equity stood at $9.9 million in 2021, then grew by 6.95% to $10.6 million in 2022, then climbed by 5.44% to $11.2 million in 2023, then fell by 7.47% to $10.3 million in 2024, then dropped by 26.34% to $7.6 million in 2025.
- According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $7.6 million, $5.1 million, and $10.3 million for Q4 2025, Q2 2025, and Q4 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 10.03 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 10.96 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 9.18 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 5.56 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 25.60 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 2.10 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 19.82 Bn |
| 10 | SciSparc | 831,418.60 | 831,418.60 | - | 7.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 7.62 Mn |
| Jun 30, 2025 | 5.14 Mn |
| Dec 31, 2024 | 10.35 Mn |
| Jun 30, 2024 | 10.48 Mn |
| Dec 31, 2023 | 11.18 Mn |
| Jun 30, 2023 | 9.89 Mn |
| Dec 31, 2022 | 10.61 Mn |
| Sep 30, 2022 | 14.11 Mn |
| Jun 30, 2022 | 14.42 Mn |
| Dec 31, 2021 | 9.92 Mn |
| Jun 30, 2021 | 8.34 Mn |
| Dec 31, 2020 | 2.56 Mn |
| Jun 30, 2020 | 1.59 Mn |
| Dec 31, 2019 | 1.15 Mn |
| Jun 30, 2019 | 2.08 Mn |
| Mar 31, 2019 | 4.57 Mn |
| Dec 31, 2018 | 4.56 Mn |
| Jun 30, 2018 | 6.39 Mn |
| Mar 31, 2018 | 8.06 Mn |
| Dec 31, 2017 | 9.57 Mn |